DDHD2: A Potential Drug Target and Biomarker (G23259)

Target Name: DDHD2

NCBI ID: G23259

DDHD2

DDHD2: A Potential Drug Target and Biomarker

Double cysteine-containing domains (DDHDs) are a class of protein structures that have been identified in a variety of organisms, including humans. These domains are characterized by the presence of two cysteine residues, which are often linked by a disulfide bond. One of the most well-studied DDHDs is DDHD2, which has been identified as a potential drug target and biomarker for various diseases.

The Importance of DDHD2 as a Drug Target

DDHD2 has been shown to play a role in a variety of cellular processes, including cell signaling, DNA replication, and metabolism. It is also involved in the regulation of cellular interactions with the extracellular matrix (ECM), which is important for tissue repair and regeneration.

One of the key reasons for the potential of DDHD2 as a drug target is its involvement in cell signaling pathways. The DAD (DNA-protein-DNA) domain in DDHD2 is known to play a role in the regulation of DNA replication and repair, while the second cysteine-containing domain (CCSD) is involved in the regulation of cellular interactions with ECM. These domains have been shown to interact with a variety of proteins, including the transcription factor, p53, which is a key regulator of DNA replication and repair.

Additionally, the N-terminal region of DDHD2 contains a unique farnesylated cysteine residue, which is known to play a role in the regulation of cellular processes such as cell signaling and metabolism. This cysteine residue is also involved in the regulation of the activity of the protein kinase, which is a key regulator of cellular processes that are important for the development and maintenance of tissues.

The Potential of DDHD2 as a Biomarker

DDHD2 has also been shown to be a potential biomarker for various diseases. For example, it has been shown to be involved in the regulation of the development and progression of cancer, and it has been shown to be involved in the regulation of neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.

In addition to its potential as a drug target, DDHD2 has also been shown to be a potential biomarker for a variety of diseases. For example, it has been shown to be involved in the regulation of the development and progression of cancer, and it has been shown to be involved in the regulation of neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.

Conclusion

In conclusion, DDHD2 is a protein structure that has been identified in a variety of organisms, including humans. It is characterized by the presence of two cysteine residues, which are often linked by a disulfide bond. The N-terminal region of DDHD2 contains a unique farnesylated cysteine residue, which is involved in the regulation of cellular processes such as cell signaling and metabolism. Additionally, the DAD (DNA-protein-DNA) domain in DDHD2 is known to play a role in the regulation of DNA replication and repair, while the second cysteine-containing domain (CCSD) is involved in the regulation of cellular interactions with ECM. These domains have been shown to interact with a variety of proteins, including the transcription factor, p53. Therefore, DDHD2 is a potential drug target and biomarker for various diseases.

Protein Name: DDHD Domain Containing 2

Functions: Phospholipase that hydrolyzes preferentially phosphatidic acid, including 1,2-dioleoyl-sn-phosphatidic acid, and phosphatidylethanolamine. Specifically binds to phosphatidylinositol 3-phosphate (PI(3)P), phosphatidylinositol 4-phosphate (PI(4)P), phosphatidylinositol 5-phosphate (PI(5)P) and possibly phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2). May be involved in the maintenance of the endoplasmic reticulum and/or Golgi structures. May regulate the transport between Golgi apparatus and plasma membrane

The "DDHD2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DDHD2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets